DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 21, 2004, from 8 a.m. to 5:30 p.m. and on October 22, 2004, from 8:30 a.m. to 12:45 p.m.

Location: Holiday Inn Gaithersburg, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Linda A. Smallwood, Center for Biologics Evaluation and Research (HFM–302), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–3514, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014519516. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 21, 2004, the committee will hear updates on the following topics: Summary of the Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) meeting discussion of new variant Creutzfeldt-Jacob disease (vCJD) transmission by transfusion in the United Kingdom and supplemental testing for human immunodeficiency virus (HIV) and hepatitis C virus (HČV). In the morning, the committee will also discuss and provide recommendations on the agency's current thinking on reentry of donors previously deferred for anti-HBc reactivity. In the afternoon, the committee will discuss and provide recommendations on the potential risk of transmission of Simian Foamy Virus (SFV) by blood transfusions. On October 22, 2004, the committee will hear updates on these topics: a summary of the Plasma Workshop held on August 31 through September 1, 2004, draft uniform donor health questionnaire acceptance guidance: review of public comments, and FDA current thinking on monitoring weight in source plasma

donors. The committee will also hear presentations, discuss and provide recommendations on the agency's current thinking on donor deferral for potential or documented infection with West Nile Virus (WNV).

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 8, 2004. Oral presentations from the public will be scheduled between approximately 10:30 a.m. and 11 a.m., 4 p.m. and 4:30 p.m. on October 21, 2004, and between approximately 11 a.m. and 11:45 a.m. on October 22, 2004. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 8, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Linda A. Smallwood, or Pearline K. Muckelvene at 301–827–1281 at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 13, 2004.

Sheila Dearybury Walcoff,

Associate Commissioner for External Relations.

[FR Doc. 04–21283 Filed 9–21–04; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Measuring the Effectiveness of the Nation's Foodservice and Retail Food Protection System; Notice of Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; satellite downlink public meeting.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting (via satellite downlink) entitled "Measuring the Effectiveness of the Nation's Foodservice and Retail Food Protection System." The purpose of the meeting is to discuss the report entitled "FDA Report on the Occurrence of Foodborne Illness Risk Factors Within Selected Institutional Foodservice, Restaurant, and Retail Food Store Facility Types (2004)" (the 2004 Report) and to provide information to the public to improve food preparation practices and food employee behaviors at institutional food service establishments, restaurants, and retail food stores. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the 2004 Report.

DATES: The satellite downlink public meeting will be held on Wednesday, October 13, 2004, from 1 p.m. to 3 p.m., eastern standard time.

ADDRESSES: The public meeting will be broadcast nationwide from FDA's broadcast studio at the Center for Devices and Radiological Health (HFZ–260), 16071–B Industrial Dr., Gaithersburg, MD. Satellite coordinates for the broadcast will be posted on FDA's Web site at http://www.fda.gov/cdrh/ocer/dcm/html/ program_calendar.html beginning September 15, 2004. See SUPPLEMENTARY INFORMATION for locations where the satellite downlink may be viewed.

FOR FURTHER INFORMATION CONTACT: Lakesha Abbey, Center for Food Safety and Applied Nutrition (HFS–625), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301–436–2440, FAX: 301–436–2672, email: *Labbey@cfsan.fda.gov*.

SUPPLEMENTARY INFORMATION:

I. Background

FDA advises other Federal agencies, State, local, and tribal governments on food safety standards for institutional food service establishments, restaurants, retail food stores, and other retail food establishments. In this advisory role, FDA works closely with these agencies to provide guidance and assistance that will enhance the regulatory programs of Federal, State, local, and tribal jurisdictions.

The purpose of the 2004 Report is to present data on foodborne illness risk factors in institutional foodservice establishments, restaurants, and retail food stores. The results contained in the 2004 Report provide insight into the effectiveness of current industry management systems and food safety regulatory programs in controlling

foodborne illness risk factors in retail and foodservice operations. Using the data from multiple collection periods, FDA hopes to evaluate trends and determine if progress is being made toward the goals of reducing the occurrence of foodborne illness risk factors.

FDA will discuss the 2004 Report during the public meeting. The presentation will be available on FDA's Web site at http://www.fda.gov on the day of the satellite broadcast.

II. Registration

Persons interested in attending the satellite downlink public meeting as a member of the studio audience should send their registration information (including name, title, business affiliation, address, and telephone and fax numbers) to the contact person (see FOR FURTHER INFORMATION CONTACT). Due to space limitations, we recommend that you register at least 5 days prior to the meeting. Seating capacity is limited to 75 persons. Registration will be accepted on a first-come-first-served basis. There is no registration fee for this public meeting, but early registration is encouraged because space is limited, and it will expedite entry into the building and its parking area. If you are interested in attending as a member of the studio audience and need any reasonable accommodations due to a disability, including a sign language interpreter, please contact Lakesha Abbey by October 6, 2003.

III. Sites for Viewing the Downlink Public Meeting

The satellite broadcast can be received at any place that has access to a steerable C-ban satellite dish. Contact your state retail food protection office or local FDA office for locations where the satellite broadcast will be available.

A videotape copy of the satellite broadcast may be available at the location where it was viewed or through the contact person listed in this document (see **FOR FURTHER INFORMATION CONTACT**). You may also borrow a copy of the videotape through FDA's ORA—U Lending Library by sending your name and mailing address along with the name, title, and date of the broadcast to *ORADLT@ora.fda.gov*.

IV. Electronic Access

The 2004 report will be available electronically on FDA's Web site at http://www.cfsan.fda.gov/~dms/retrsk2.html.

Dated: September 16, 2004.

Jeffrev Shuren,

Assistant Commissioner for Policy.
[FR Doc. 04–21314 Filed 9–17–04; 4:06 pm]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Transmissible Spongiform Encephalopathies Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 14, 2004, from 8 a.m. to 5:30 p.m.

Location: Hilton Hotel, 8727 Colesville Rd., Silver Spring, MD 20910.

Contact Person: William Freas or Sheila D. Langford, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512392. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 14, 2004, the committee will hear updates on the following issues: USDA-licensed tests for the diagnosis of bovine spongiform encephalopathy (BSE) and other transmissible spongiform encephalopathies (TSE), review of the worldwide BSE situation, new FDA/ Center for Food Safety and Applied Nutrition BSE-food safety rules, and labeling claims for TSE clearance studies for plasma derivative products. The committee will then discuss and make recommendations regarding presumptive transfusion transmissions of variant Creutzfeldt Jakob Disease (vCJD) and current FDA-recommended safeguards.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending

before the committee. Written submissions may be made to the contact person by October 5, 2004. Oral presentations from the public will be scheduled between approximately 9:20 a.m. and 9:50 a.m., and 2:45 p.m. and 3:15 p.m. on October 14, 2004. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 7, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact William Freas or Sheila D. Langford at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 15, 2004.

Sheila Dearybury Walcoff,

 $Associate\ Commissioner\ for\ External\ Relations.$

[FR Doc. 04–21282 Filed 9–21–04; 8:45 am] **BILLING CODE 4160–01–S**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Food and Drug Administration Report on the Occurrence of Foodborne Illness Risk Factors Within Selected Institutional Foodservice, Restaurant, and Retail Food Store Facility Types (2004); Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a report entitled "FDA Report on the Occurrence of Foodborne Illness Risk Factors Within Selected Institutional Foodservice, Restaurant, and Retail Food Store Facility Types (2004)" (the 2004 Report). The 2004 Report summarizes results from a data collection conducted in 2003 on risk factors which have been identified as